Journal ArticleDOI
Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients
Javier Loricera,Ricardo Blanco,José L. Hernández,Santos Castañeda,Antonio Mera,Eva Perez-Pampin,Peiró E,A. Humbría,Jaime Calvo-Alén,Elena Aurrecoechea,Javier Narváez,A. Sanchez-Andrade,Paloma Vela,Elvira Díez,C. Mata,Pau Lluch,Concepción Moll,Íñigo Hernández,Vanesa Calvo-Río,Francisco Ortiz-Sanjuán,Carmen González-Vela,Trinitario Pina,Miguel A. González-Gay +22 more
TLDR
TCZ therapy leads to rapid and maintained improvement in patients with refractory GCA and/or with unacceptable side effects related to corticosteroids, however, the risk of infection should be kept in mind when using this drug in Patients with GCA.About:
This article is published in Seminars in Arthritis and Rheumatism.The article was published on 2015-06-01. It has received 119 citations till now. The article focuses on the topics: Giant cell arteritis & Polymyalgia rheumatica.read more
Citations
More filters
Journal ArticleDOI
Trial of Tocilizumab in Giant-Cell Arteritis.
John H. Stone,Katie Tuckwell,Sophie Dimonaco,Micki Klearman,Martin Aringer,Daniel Engelbert Blockmans,Elisabeth Brouwer,Maria C. Cid,Bhaskar Dasgupta,Juergen Rech,Carlo Salvarani,Georg Schett,Hendrik Schulze-Koops,Robert Spiera,Sebastian Unizony,Neil Collinson +15 more
TL;DR: Tocilizumab, received weekly or every other week, combined with a 26‐week prednisone taper was superior to either 26‐ week or 52‐weekprednisone tapering plus placebo with regard to sustained glucocorticoid‐free remission in patients with giant‐cell arteritis.
Journal ArticleDOI
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Bernhard Hellmich,Ana Filipa Águeda,Sara Monti,Frank Buttgereit,Hubert de Boysson,Elisabeth Brouwer,Rebecca Cassie,Maria C. Cid,Bhaskar Dasgupta,Christian Dejaco,Gulen Hatemi,Nicole Hollinger,Alfred Mahr,Susan P Mollan,Chetan Mukhtyar,Cristina Ponte,Carlo Salvarani,Rajappa Sivakumar,Xinping Tian,Gunnar Tomasson,Carl Turesson,Wofgang Schmidt,Peter M. Villiger,Richard A. Watts,Chris Young,Raashid Luqmani +25 more
TL;DR: The recommendations for the management of LVV have been updated to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.
Journal ArticleDOI
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Peter M. Villiger,Sabine Adler,Stefan Kuchen,Felix Wermelinger,Diana Dan,Veronika Fiege,Lukas Bütikofer,Michael Seitz,Stephan Reichenbach +8 more
TL;DR: The findings show, for the first time in a trial setting, the efficacy of tocilizumab in the induction and maintenance of remission in patients with giant cell arteritis.
Journal ArticleDOI
Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).
Boris Bienvenu,K.H. Ly,Marc Lambert,Christian Agard,Marc André,Ygal Benhamou,Bernard Bonnotte,H. De Boysson,Olivier Espitia,G. Fau,Anne-Laure Fauchais,Françoise Galateau-Salle,Julien Haroche,E. Héron,F.X. Lapébie,Eric Liozon,L.B. Luong Nguyen,J. Magnant,Alain Manrique,M. Matt,M. de Menthon,Luc Mouthon,Xavier Puéchal,Grégory Pugnet,Thomas Quemeneur,Alexis Régent,David Saadoun,Maxime Samson,Damien Sène,P. Smets,Cécile Yelnik,Laurent Sailler,Alfred Mahr +32 more
TL;DR: The recommendations, which will be updated regularly, are intended to guide and harmonize the standards of GCA management.
Journal ArticleDOI
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry).
Marta Perez-de-Lis,Soledad Retamozo,Alejandra Flores-Chávez,Belchin Kostov,Roberto Pérez-Alvarez,Pilar Brito-Zerón,Manuel Ramos-Casals +6 more
TL;DR: Following the increased use of biologics, the number and diversity of induced autoimmune diseases is increasing exponentially and management of these disorders will be an increasing clinical challenge in the daily practice in the next years.
References
More filters
Journal ArticleDOI
The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee.
Frederick Wolfe,Hugh A. Smythe,Muhammad B. Yunus,Robert M. Bennett,Claire Bombardier,Don L. Goldenberg,Peter Tugwell,Stephen M. Campbell,Micha Abeles,Patricia Clark,Adel G. Fam,Stephen J. Farber,Justus J. Fiechtner,C. Michael Franklin,Robert A. Gatter,Daniel Hamaty,James A. Lessard,Alan S. Lichtbroun,Alfonse T. Masi,Glenn A. McCain,W. John Reynolds,Thomas J. Romano,I. Jon Russell,Robert P. Sheon +23 more
TL;DR: Criteria for the classification of fibromyalgia are widespread pain in combination with 2) tenderness at 11 or more of the 18 specific tender point sites, and no exclusions are made for the presence of concomitant radiographic or laboratory abnormalities.
Journal ArticleDOI
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Gene G. Hunder,Gene G. Hunder,Daniel A. Bloch,Daniel A. Bloch,Beat A. Michel,Mary Betty Stevens,Mary Betty Stevens,William P. Arend,William P. Arend,Leonard H. Calabrese,Leonard H. Calabrese,Steven M. Edworthy,Steven M. Edworthy,Anthony S. Fauci,Anthony S. Fauci,Randi Y. Leavitt,J. T. Lie,J. T. Lie,Robert W. Lightfoot,Robert W. Lightfoot,Alfonse T. Masi,Alfonse T. Masi,Dennis J. McShane,Dennis J. McShane,John A. Mills,John A. Mills,Stanley L. Wallace,Stanley L. Wallace,Nathan J. Zvaifler,Nathan J. Zvaifler +29 more
TL;DR: Criteria for the classification of giant cell (temporal) arteritis were developed by comparing 214 patients who had this disease with 593 patients with other forms of vasculitis, and 2 other variables were included: scalp tenderness and claudication of the jaw or tongue or on deglutition.
Journal ArticleDOI
Polymyalgia rheumatica and giant-cell arteritis.
Journal ArticleDOI
Directing transition from innate to acquired immunity: defining a role for IL-6.
TL;DR: Appropriate control of leukocyte recruitment and activation is a fundamental requirement for competent host defense and resolving inflammation and particular attention will be given to the regulatory properties of the soluble IL-6 receptor and how its activity may affect chronic disease progression.
Journal ArticleDOI
Medium- and Large-Vessel Vasculitis
TL;DR: The mechanisms that contribute to the causes of giant-cell arteritis are reviewed, with an emphasis on immune-mediated injury to arteries.